Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Alamar Biosciences, Inc.NASDAQ: ALMR
Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue of $2.19M in Q2 FY2026
Q2 FY2026 deferred revenue was $2.19M.
Context
- Deferred revenue amounted to 0.6% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 470K USD
- Year-over-year change
- -18.3%
- 1-year CAGR
- -18.3%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 470K | -18.3% |
| FY2024 | 2024-12-31 | 575K | — |
Deferred Revenue vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's Jun 2026 deferred revenue of $2.19M is the 5th highest of the 9 companies compared; the peer median is $7.09M.
- Deferred revenue amounts to 0.6% of total assets for ALMR, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $31.76M | +4.3% | +16.1% | 1.2% | |
| Sep 2026 | $22.96M | +3.7% | +44.8% | 2.2% | |
| Mar 2026 | $16.33M | +7.1% | — | 2.1% | |
| Mar 2026 | $13.84M | -20.1% | +39.2% | 2.2% | |
ALMRAlamar Biosciences, Inc. | Jun 2026 | $2.19M | — | — | 0.6% |
| Mar 2026 | $334K | -19.1% | +36.9% | 0.1% | |
| Mar 2026 | $91K | -41.3% | — | 0.0% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ALMR) | $7.09M | -19.1% | +38.0% | 0.7% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 26.77M | 30M |
| Short-term Investments | 52.59M | 0 |
| Net Receivables | 7.32M | 12.75M |
| Inventory | 14.41M | 38.48M |
| Other Current Assets | 5.61M | 13.47M |
| Total Current Assets | 106.7M | 94.71M |
| Property, Plant & Equipment (Net) | 35.1M | 36.63M |
| Goodwill | 0 | 0 |
| Intangible Assets | 2.04M | 1.99M |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 5.67M | 6.67M |
| Total Non-current Assets | 42.81M | 45.29M |
| Total Assets | 149.51M | 139.99M |
| Account Payables | 6.19M | 5.87M |
| Short-term Debt | 0 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 575K | 470K |
| Other Current Liabilities | 5.42M | 7.59M |
| Total Current Liabilities | 16.59M | 23.73M |
| Long-term Debt | 0 | 9.81M |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 235.14M | 235.84M |
| Total Non-current Liabilities | 266.33M | 275.22M |
| Total Liabilities | 282.92M | 298.95M |
| Common Stock | 1K | 1K |
| Retained Earnings | (138.96M) | (168.78M) |
| Accumulated OCI | 149K | (72K) |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (133.41M) | (158.95M) |
| Total Debt | 33.1M | 41.47M |
| Net Debt | 6.33M | 11.47M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.